Breaking News
0

2 Reasons Merck Is A Compelling Defensive Play For Current Markets

By Investing.com (Haris Anwer/Investing.com)Stock MarketsJan 08, 2019 03:20
ca.investing.com/analysis/2-reasons-merck-is-a-compelling-defensive-play-for-current-markets-200198072
2 Reasons Merck Is A Compelling Defensive Play For Current Markets
By Investing.com (Haris Anwer/Investing.com)   |  Jan 08, 2019 03:20
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

As 2019 begins, it looks as if markets are picking up where they left off at the end of last year, when volatility reigned and high-flying growth stocks started losing their luster. We believe volatility will continue and growth stocks will remain under pressure on increasing concerns the decade-long US economic expansion could be coming to an end.

During times of market gyrations and increasing economic uncertainty, having a few income stocks in one's portfolio is a good defense. In fact, in 2018 defensive stocks outperformed the broader market. In this space, we strongly favor the global healthcare provider Merck (NYSE:MRK) for two reasons—its roster of top selling meds and the company's dependable dividend.

1. Strong Growth Momentum; Powerhouse Drugs

MRK Weekly
MRK Weekly

Over the past three years, Merck has consistently exceeded analysts expectations on earnings. This impressive winning streak powered its shares higher. Indeed, for 2018 it was the best performer among the 30 mega cap companies listed on the Dow Jones Industrial Average, gaining 30% for the year.

We don’t expect that pace of growth to slow anytime soon either. Merck's cancer immunotherapy drug, Keytruda, continues to capture market share. In the first nine of months of 2018, Keytruda sales doubled, reaching a whopping $5 billion. The drug has become a core component of Merck’s growth, particularly in the large and lucrative area of lung cancer.

Earlier this year the drug showed what medical experts called practice-changing results when combined with chemotherapy. As well, just last month, Keytruda gained EU approval for use on adults who've undergone surgery to remove melanomas. According to Merck, it's the first approval for the drug as an auxiliary treatment in the European Union.

Some analysts expect the majority of previously untreated patients will start taking the drug as well. According to EvaluatePharma projections, it could bring in $12.69 billion in annual sales by 2024. Helped by Keytruda’s remarkable success, Merck plans to invest $16 billion on new capital projects through 2022, a 33% surge over what the company announced it would spend in early 2018.

While Merck’s cancer treatment is grabbing much of the attention, the company’s other drugs are also performing well. HPV vaccine Gardasil’s sales were up 55% in the third-quarter from the year ago period, while diabetes medications Januvia and Janumet brought in $1.49 billion in sales during the same period.

2. Reliable Payouts

One of the primary reasons to bet on a dividend paying stock is for its benefits during market highs and lows. Which means the focus should be on the company's history of reliably paying dividends.

With its forward dividend yield of about 3%, Merck has made returning capital to investors a top priority. Since at least 1970, the company has never missed a quarterly payout. Merck's dividend has grown at an annualized rate of 5.5% since 2010—beating the rate of inflation. After delivering a 15% hike in October, Merck now pays $0.55 a share every three months.

The company has also been returning capital to stockholders in recent years via share buybacks, further boosting its total yield. In October, the company announced that it plans to buy back an additional $10 billion worth of outstanding shares.

Any future dividend growth will depend on both earnings and the company's payout ratio. Merck's current payout ratio is 66%, suggesting it's in a comfortable position to continue the current dividend growth strategy.

Bottom Line

If you’re looking to play it safe in 2019, Merck is worth considering. At its current $75.43 share price, with a dividend yield that's a bit higher than the pharmaceutical industry average, it's a good shelter for conservative, long-term investors.

2 Reasons Merck Is A Compelling Defensive Play For Current Markets
 

Related Articles

2 Reasons Merck Is A Compelling Defensive Play For Current Markets

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email